Skip to main content
Clinical Trials/NL-OMON21445
NL-OMON21445
Recruiting
N/A

Profiling Parkinson’s disease

Amsterdam UMC, location VUmc0 sites1,515 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Parkinson's disease
Sponsor
Amsterdam UMC, location VUmc
Enrollment
1515
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Amsterdam UMC, location VUmc

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a patient must meet ALL of the following criteria:
  • \- Recently diagnosed with PD (N\=625; time since Parkinson diagnosis \= 2 years) or not recently diagnosed with PD (N\=625; time since Parkinson diagnosis \> 2 \& \= 10 years) (Time since Parkinson diagnosis (in years) made by a neurologist according to the Movement Disorder Society clinical diagnostic criteria for Parkinson's disease; In order to obtain a good representation of the PD population an even distribution with respect to gender and age (age categories: \<55 years, 55\-65 years and \>65 years) in both patient groups, will be attempted;
  • \- 18 years or older;
  • \- Able to read and understand Dutch;
  • \- Providing IRB\-approved Informed Consent;
  • \- Willing, competent and able to comply with all aspects of the protocol, including follow\-up schedule and biospecimen collections.
  • \- 18 years or older;
  • \- Healthy (self\-report);
  • \- Similar distribution with respect to gender and age as the patient groups will be attempted;
  • \- Providing IRB\-approved Informed Consent;

Exclusion Criteria

  • A potential participant who meets ANY of the following criteria will be excluded from participation in this study:
  • \- Patients who received brain surgery for Parkinson’s disease, patients who currently use levodopa continuous intestinal gel or patients who are currently receiving apomorphine treatment.
  • \- Presence of co\-morbidities that would hamper interpretation of parkinsonian disability, in the opinion of the investigator;
  • \- MoCa score of \=16 (indicates dementia);
  • \- Unwillingness to be informed of unexpected medical findings;
  • \- Note: patients with a disease duration of \= 2 yrs, are excluded if:
  • \- they are current, recent or past participant in The Personalized Parkinson Project (de Parkinson op maat studie”) from Radboudumc.
  • \- Patients with a disease duration of \> 2 \& \= 10 yrs, are only excluded if they are currently a participant in The Personalized Parkinson Project (de Parkinson op maat studie”) from Radboudumc.
  • \- A history of neurological disorders that affect the brain or central nervous system;
  • \- Abnormal findings at general neurological examination;

Outcomes

Primary Outcomes

Not specified

Similar Trials